NMTR News and Press, 9 Meters Biopharma Inc. From 06/30/22

Initial Draw of $20 Million to Support Funding Phase 3 Development of Vurolenatide in Short Bowel Syndrome RALEIGH, NC / ACCESSWIRE / June 30, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digesti...

Phase 2 VIBRANT study identifies a dose and dosing interval with >25% improvement in the primary endpoint of 24-hour mean total stool output reduction over 6 weeks Vurolenatide was generally well tolerated with no adverse events leading to early study withdrawal End-of-Phase 2 ...

Buying Penny Stocks on June 24th? Here’s What You Need to Know After a bullish day of trading penny stocks and blue chips, there is a lot that investors need to know. For starters, right now, there is a sizable amount of volatility across the board. This means that penny stocks a...

Buying Penny Stocks on June 23rd? Here’s What You Need to Know With another day of trading penny stocks, there is a lot for investors to consider. As a result, investors need to understand exactly what is going on and how to take advantage. This involves having a trading strategy...

9 Meters Biopharma (NASDAQ:NMTR) stock fell ~54% on June 21 after the company said it will not continue a phase 3 trial of larazotide to treat Celiac disease. The company said that based on consultation with an independent statistician, it decided that the additional number of patie...

Additional analyses to determine if a subgroup of patients and/or symptoms may have been responsive to treatment Company remains on track to deliver vurolenatide Phase 2 short bowel syndrome results by end of month RALEIGH, NC / ACCESSWIRE / June 21, 2022 / 9 Meters Biopharma, In...

RALEIGH, NC / ACCESSWIRE / June 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced the Company's participation in the 2022 BIO International Convention on June 13 - 16, 202...

RALEIGH, NC / ACCESSWIRE / May 19, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced that the company will host an exhibit at Digestive Disease Week (DDW) which takes place Ma...

RALEIGH, NC / ACCESSWIRE / May 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced that Matthew Bryant, PharmD, Vice President of Medical Affairs at 9 Meters, delivered a p...

9 Meters Biopharma press release (NASDAQ:NMTR): Q1 GAAP EPS of -$0.04. Cash and cash equivalents of approximately $37.2M. The company anticipates its cash runway is sufficient to fund the ongoing clinical programs into the second quarter of 2023, including initiation of the Phase 3 vurolenati...